FIELD: medicine.
SUBSTANCE: invention relates to use of an agent for adjuvant therapy for treating a SART2-positive malignant tumour, which has a marked inhibitory effect on metastasis and tumour recurrence, while causing few side effects. Agent for adjuvant therapy contains peptide having 4 linked CTL epitopes as an active ingredient.
EFFECT: disclosed is an agent for adjuvant therapy.
12 cl, 5 dwg, 3 tbl, 1 ex
Authors
Dates
2024-10-30—Published
2020-12-25—Filed